A nationwide longitudinal study on risk factors for progression of anal intraepithelial neoplasia grade 3 to anal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 577 KB, PDF-dokument

Little is known about risk factors for progression of high-grade anal intraepithelial neoplasia (AIN) to anal squamous cell carcinoma (ASCC). In this large, population-based study, we assess the role of factors related to immune status for the risk of ASCC among individuals from the general population with a diagnosis of AIN3. Individuals diagnosed with AIN3 during 1985-2016 were identified in the Danish Pathology Registry and followed for subsequent development of ASCC. The study population was linked to the National Patient Registry, the Danish Prescription Registry and the Danish HIV Cohort Study for information on autoimmune disease, genital warts and HIV status. To study the progression rate, Cox regression models with hazard ratios (HR) and 95% confidence intervals (CI) were applied with time since AIN3 as the underlying time scale and with adjustment for age at AIN3 diagnosis, year of AIN3 diagnosis and sex. The study population comprised 1222 individuals with AIN3 contributing 12 824 person-years of follow-up. Ninety-seven individuals (7.9%) developed ASCC. Individuals registered with an autoimmune disease or genital warts before and/or after the AIN3 diagnosis had an increased rate of progression to ASCC compared to individuals without these conditions. People living with HIV had a higher progression rate than HIV-negative individuals (HR = 4.25; 95% CI: 1.87-9.65) with the highest progression rate among those with CD4 count ≤200 cells/μL. These associations may be caused by an interplay between HPV infection and immunosuppression.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind151
Udgave nummer8
Sider (fra-til)1240-1247
ISSN0020-7136
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Joel M. Palefsky received grant support, SAB, and speaker's fee from Merck, and acted as a consultant for Antiva Biosciences, Virion Biotechnologies and Virion Therapeutics. Finally, he has stock options in Virion Therapeutics. Susanne K. Kjaer previously received speaker's fee from Merck, and a research grant through her institution from Merck. All other authors report no conflicts of interest.

Publisher Copyright:
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

ID: 320050529